When combined with age and genetic risk factor, test is 94% accurate
Up to two decades before people develop the characteristic memory loss and confusion of Alzheimer’s disease, damaging clumps of protein start to build up in their brains. Now, a blood test to detect such early brain changes has moved one step closer to clinical use.
Researchers from Washington University School of Medicine in St. Louis report that they can measure levels of the Alzheimer’s protein amyloid beta in the blood and use such levels to predict whether the protein has accumulated in the brain. When blood amyloid levels are combined with two other major Alzheimer’s risk factors – age and the presence of the genetic variant APOE4 – people with early Alzheimer’s brain changes can be identified with 94% accuracy, the study found.
The findings, published Aug. 1 in the journal Neurology, represent another step toward a blood test to identify people on track to develop Alzheimer’s before symptoms arise. Surprisingly, the test may be even more sensitive than the gold standard – a PET brain scan – at detecting the beginnings of amyloid deposition in the brain.
Such a test may become available at doctors’ offices within a few years, but its benefits will be much greater once there are treatments to halt the disease process and forestall dementia. Clinical trials of preventive drug candidates have been hampered by the difficulty of identifying participants who have Alzheimer’s brain changes but no cognitive problems. The blood test could provide a way to efficiently screen for people with early signs of disease so they can participate in clinical trials evaluating whether drugs can prevent Alzheimer’s dementia.
“Right now we screen people for clinical trials with brain scans, which is time-consuming and expensive, and enrolling participants takes years,” said senior author Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology. “But with a blood test, we could potentially screen thousands of people a month. That means we can more efficiently enroll participants in clinical trials, which will help us find treatments faster, and could have an enormous impact on the cost of the disease as well as the human suffering that goes with it.”
The test, an earlier version of which first was reported two years ago, uses a technique called mass spectrometry to precisely measure the amounts of two forms of amyloid beta in the blood: amyloid beta 42 and amyloid beta 40. The ratio of the two forms goes down as the amount of amyloid beta deposits in the brain goes up.
The current study involved 158 adults over age 50. All but 10 of the participants in the new study were cognitively normal, and each provided at least one blood sample and underwent one PET brain scan. The researchers classified each blood sample and PET scan as amyloid positive or negative, and found that the blood test from each participant agreed with his or her PET scan 88 percent of the time, which is promising but not accurate enough for a clinical diagnostic test.
In an effort to improve the test’s accuracy, the researchers incorporated several major risk factors for Alzheimer’s. Age is the largest known risk factor; after age 65, the chance of developing the disease doubles every five years. A genetic variant called APOE4 raises the risk of developing Alzheimer’s three- to fivefold. And gender also plays a role: Two out of three Alzheimer’s patients are women.
When the researchers included these risk factors in the analysis, they found that age and APOE4 status raised the accuracy of the blood test to 94%. Sex did not significantly affected the analysis.
“Sex did affect the amyloid beta ratio, but not enough to change whether people were classified as amyloid positive or amyloid negative, so including it didn’t improve the accuracy of the analysis,” said first author Suzanne Schindler, MD, PhD, an assistant professor of neurology.
Further, the results of some people’s blood tests initially were considered false positives because the blood test was positive for amyloid beta but the brain scan came back negative. But some people with mismatched results tested positive on subsequent brain scans taken an average of four years later. The finding suggests that, far from being wrong, the initial blood tests had flagged early signs of disease missed by the gold-standard brain scan.
There is growing consensus among neurologists that Alzheimer’s treatment needs to begin as early as possible, ideally before any cognitive symptoms arise. By the time people become forgetful, their brains are so severely damaged no therapy is likely to fully heal them. But testing preventive treatments requires screening thousands of healthy people to find a study population of people with amyloid build-up and no cognitive problems, a slow and expensive process.
As part of the study, the researchers analyzed the enrollment process for a prominent Alzheimer’s prevention trial called the A4 study that used PET scans to confirm the presence of early Alzheimer’s brain changes in potential participants. They concluded that prescreening with a blood test followed by a PET scan for confirmation would have reduced the number of PET scans needed by two thirds. Unlike blood tests, which cost a few hundred dollars, each PET scan costs upward of $4,000. A single site can only run a few dozen PET brain scans a month, because PET scanners are primarily reserved for patient care, not research studies.
“If you want to screen an asymptomatic population for a prevention trial, you would have to screen, say, 10,000 people just to get 1,500 or 2,000 that would qualify,” Bateman said. “Reducing the number of PET scans could enable us to conduct twice as many clinical trials for the same amount of time and money. It’s not the $4,000 per PET scan that we’re worried about. It’s the millions of patients that are suffering while we don’t have a treatment. If we can run these trials faster, that will get us closer to ending this disease.”
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Alzheimer’s charity demands 1 percent of GDP spent on research to eradicate conditionon December 2, 2019 at 11:11 am
The charity said it would allow scientists to transform research to pick up early signs of diseases like Alzheimer’s while more money would also help the NHS prepare for new developments in treatment ...
- Biogen's shares drop on critical view of Alzheimer's dataon December 2, 2019 at 11:01 am
Biogen BIIB, -2.56% shares fell 2.6% after an analyst scoffed at the possibility of a Food and Drug Administration approval for the company's experimental Alzheimer's disease treatment. "There are so ...
- Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgradeon December 2, 2019 at 10:55 am
Biogen Inc (NASDAQ: BIIB) shares gained more than 25% earlier this year when the company said it planned a regulatory filing for its Alzheimer's drug aducanumab following a new data analysis. Ahead of ...
- New drug shows promising results in the treatment of Alzheimer’son December 2, 2019 at 10:19 am
OMAHA, Neb. (WOWT/Gray News) - Alzheimer’s disease affects some 5 million people in the United States, and as the population ages, doctors estimate those affected will more than double by 2050. A new ...
- Predicting Alzheimer's-like memory loss before it strikeson December 2, 2019 at 8:38 am
For someone with Alzheimer's disease, there's no turning back the clock. By the time memory loss and other worrisome signs appear, cognitive decline has already begun. "Being able to predict deficits ...
- Biogen’s Alzheimer’s Drug Won’t Get Approved, Analyst Sayson December 2, 2019 at 7:31 am
On Monday morning, he stuck it into Biogen. In a scathing note, Skorney laid out the case that Biogen’s experimental Alzheimer’s drug aducanumab won’t get approved by the Food and Drug Administration.
- CorTechs Labs Presents Findings Regarding Alzheimer’s Disease at the Radiological Society of North America’s (RSNA) 2019 Annual Meetingon December 2, 2019 at 7:05 am
In addition to technical exhibits on both the main floor and AI Showcase, the company will present their findings from a recent study titled: “Determining Brain Age Using Machine Learning Combined ...
- Grifols to present latest Alzheimer's clinical trial resultson December 2, 2019 at 6:28 am
BARCELONA, Spain, Dec. 2, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, will present the final and complete clinical, ...
- Eisai and Biogen's Joint Investigational Asset BAN2401 Data to be Presented at Clinical Trials on Alzheimer's Disease Conferenceon December 2, 2019 at 6:18 am
WOODCLIFF LAKE, N.J., Dec. 2, 2019 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today new data from the company's rich dementia pipeline, including ...
- INmune Bio, Inc. Announces First Alzheimer’s Disease Patient Dosed in XPro1595 Studyon December 2, 2019 at 5:00 am
LA JOLLA, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, ...
via Bing News